SHANGHAI, Sept. 5, 2012 /PRNewswire/ -- ShanghaiBio Corporation and Ingenuity® Systems have signed a collaboration agreement enabling ShanghaiBio Corporation to extend its current lab service offering to include Ingenuity solutions for downstream analysis and interpretation of genomics data. ShanghaiBio Corporation will complement their sequencing, genotyping and gene expression lab services by creating a bundled solution with Ingenuity's applications, which combine analytics and biomedical content to help get actionable insights from experiments.
ShanghaiBio Corporation, one of the leading genomics and biomarker service providers with all integrated microarray/next-generation sequencing/PCR/biobanking/pathology capabilities based in China and US, supports global pharmaceutical and biotechnology companies' and academic institutes' drug discovery efforts specifically in the areas of translational medicine and systems biology. By offering Ingenuity products, ShanghaiBio Corporation supports the complete workflow from study design to bioinformatic analysis, providing its customers with high-quality data and easily interpretable results.
Jason Jin, CEO of ShanghaiBio Corporation, stated, "China is rapidly expanding its investment in the innovative life sciences, drug R&D, and molecular diagnostics sectors. Many organizations including pharmaceutical companies, biotech firms and universities have growing programs for translational medicine research and are faced with analyzing and understanding complex data. With Ingenuity's solutions, we are helping our customers rapidly obtain a detailed assessment of their data so they can move to the next phase of their research."
High throughput experiments generate a significant amount of data, and obtaining insights from that data can be a time-consuming, laborious process. Ingenuity's suite of products, based on the Ingenuity Knowledge Bas
|SOURCE ShanghaiBio Corporation|
Copyright©2012 PR Newswire.
All rights reserved